CA3111158A1 - Agent for treatment of dermatological disorders - Google Patents
Agent for treatment of dermatological disorders Download PDFInfo
- Publication number
- CA3111158A1 CA3111158A1 CA3111158A CA3111158A CA3111158A1 CA 3111158 A1 CA3111158 A1 CA 3111158A1 CA 3111158 A CA3111158 A CA 3111158A CA 3111158 A CA3111158 A CA 3111158A CA 3111158 A1 CA3111158 A1 CA 3111158A1
- Authority
- CA
- Canada
- Prior art keywords
- polypeptide
- seq
- ngf
- ulcers
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/48—Nerve growth factor [NGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Psychology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18194930.6 | 2018-09-17 | ||
| EP18194930 | 2018-09-17 | ||
| EP18203665.7 | 2018-10-31 | ||
| EP18203665 | 2018-10-31 | ||
| PCT/EP2019/074767 WO2020058217A1 (en) | 2018-09-17 | 2019-09-17 | Agent for treatment of dermatological disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3111158A1 true CA3111158A1 (en) | 2020-03-26 |
Family
ID=67989007
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3111158A Pending CA3111158A1 (en) | 2018-09-17 | 2019-09-17 | Agent for treatment of dermatological disorders |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20220064243A1 (https=) |
| EP (1) | EP3852785A1 (https=) |
| JP (2) | JP2022502359A (https=) |
| KR (1) | KR20210061388A (https=) |
| CN (1) | CN113226350B (https=) |
| AU (1) | AU2019343514B2 (https=) |
| BR (1) | BR112021003820A2 (https=) |
| CA (1) | CA3111158A1 (https=) |
| MA (1) | MA53636A (https=) |
| MX (1) | MX2021002983A (https=) |
| WO (1) | WO2020058217A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023536229A (ja) * | 2020-07-27 | 2023-08-24 | ヒューマン セル カンパニー | Ｎｇｆバリアント、産生、組成物、及び治療的使用 |
| CA3207296A1 (en) * | 2021-01-06 | 2022-07-14 | The Penn State Research Foundation | Methods and materials for treating hair loss |
| US12268677B2 (en) | 2022-04-27 | 2025-04-08 | The Penn State Research Foundation | 4-aminopyridine (4-AP) and bone morphogenetic protein 2 (BMP-2) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2213861T3 (es) | 1998-10-09 | 2004-09-01 | Scil Proteins Gmbh | Procedimiento de obtencion de ngf-beta activa. |
| EP1482966B1 (en) | 2002-03-12 | 2014-05-14 | Bio-Click Technologies Ltd | Method and composition for treating skin wounds with epidermal growth factor |
| ITRM20060367A1 (it) * | 2006-07-13 | 2008-01-14 | Lay Line Genomics Spa | Muteine del hngf usi terapeutici e composizioni farmaceutiche |
| WO2010128519A1 (en) | 2009-05-04 | 2010-11-11 | Kumar C Jairaj | A method for detecting neuropathy and predicting foot ulcer development in human beings with health conditions like diabetes mellitus |
| CN104203264B (zh) | 2011-12-19 | 2018-08-28 | 瓦克化学有限公司 | 新型proNGF突变体及其在生产β-NGF中的用途 |
| US20180086805A1 (en) * | 2016-05-20 | 2018-03-29 | Chiesi Farmaceutici S.P.A. | proNGF mutants and uses thereof for the preparation of NGF mutants |
-
2019
- 2019-09-17 JP JP2021514556A patent/JP2022502359A/ja active Pending
- 2019-09-17 CA CA3111158A patent/CA3111158A1/en active Pending
- 2019-09-17 KR KR1020217011307A patent/KR20210061388A/ko not_active Ceased
- 2019-09-17 BR BR112021003820-5A patent/BR112021003820A2/pt unknown
- 2019-09-17 CN CN201980060757.0A patent/CN113226350B/zh active Active
- 2019-09-17 MA MA053636A patent/MA53636A/fr unknown
- 2019-09-17 WO PCT/EP2019/074767 patent/WO2020058217A1/en not_active Ceased
- 2019-09-17 MX MX2021002983A patent/MX2021002983A/es unknown
- 2019-09-17 US US17/277,240 patent/US20220064243A1/en not_active Abandoned
- 2019-09-17 AU AU2019343514A patent/AU2019343514B2/en active Active
- 2019-09-17 EP EP19769794.9A patent/EP3852785A1/en active Pending
-
2025
- 2025-03-28 US US19/093,959 patent/US20250277010A1/en active Pending
- 2025-05-07 JP JP2025077313A patent/JP2025125558A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022502359A (ja) | 2022-01-11 |
| BR112021003820A2 (pt) | 2021-05-25 |
| AU2019343514A1 (en) | 2021-04-15 |
| EP3852785A1 (en) | 2021-07-28 |
| JP2025125558A (ja) | 2025-08-27 |
| KR20210061388A (ko) | 2021-05-27 |
| MA53636A (fr) | 2021-12-22 |
| AU2019343514B2 (en) | 2025-09-25 |
| CN113226350B (zh) | 2024-09-10 |
| MX2021002983A (es) | 2021-05-14 |
| WO2020058217A1 (en) | 2020-03-26 |
| US20220064243A1 (en) | 2022-03-03 |
| CN113226350A (zh) | 2021-08-06 |
| US20250277010A1 (en) | 2025-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250277010A1 (en) | Agent for treatment of dermatological disorders | |
| JP6846063B2 (ja) | 異常な皮膚瘢痕化の治療 | |
| US20210038690A1 (en) | Promoting epithelial regeneration using heparin binding epidermal growth factor like growth factor | |
| KR20080031405A (ko) | 상피 재생의 촉진 | |
| EP4031117B1 (en) | Ngf mutant for use in treatment or prevention of ophthalmic disorders | |
| US12357674B2 (en) | Methods for promoting wound healing and hair growth comprising GDNF administration | |
| US20200000890A1 (en) | Use of apc analogue for wound healing | |
| RU2799211C2 (ru) | Средство для лечения дерматологических заболеваний | |
| HK40047629A (zh) | 皮肤病治疗剂 | |
| HK40047629B (zh) | 皮肤病治疗剂 | |
| RU2812055C1 (ru) | Агент для использования при лечении или профилактике офтальмологических расстройств | |
| WO2022204331A1 (en) | Compositions comprising branched kgf-2 derived peptides and methods for use in ocular treatment | |
| AU2004238332A1 (en) | Novel fibroblast growth factors and methods of use thereof | |
| HK1230520A1 (en) | Use of apc analogue for wound healing |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220922 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240913 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240913 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240913 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250414 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250813 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250826 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250912 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250912 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250929 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250929 |